Loading...
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The last earnings update was 95 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Mesoblast (MSB) | -0.4% | -14.2% | -10.6% | -13.6% | -27.5% | -80.1% |
AU Biotechs | -2.1% | -4.4% | 6.6% | 19.4% | 78.6% | 132.7% |
AU Market | 0.7% | 4.7% | 6.7% | 1.6% | 24.9% | 4.2% |
Is Mesoblast undervalued based on future cash flows and its price relative to the stock market?
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-09-30) in USD | $-0.10 |
ASX:MSB Share Price ** | ASX (2019-02-19) in AUD | A$1.18 |
ASX:MSB Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $0.84 |
Global Biotechs Industry PE Ratio | Median Figure of 74 Publicly-Listed Biotechs Companies | 23.16x |
Australia Market PE Ratio | Median Figure of 559 Publicly-Listed Companies | 15.9x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Mesoblast.
Calculation | Outcome | |
---|---|---|
PE Ratio | = ASX:MSB Share Price ÷ EPS (both in USD) = 0.84 ÷ -0.10 |
-8.32x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | -8.32x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
67.5%per year |
Global Biotechs Industry PEG Ratio | Median Figure of 57 Publicly-Listed Biotechs Companies | 1.55x |
Australia Market PEG Ratio | Median Figure of 361 Publicly-Listed Companies | 1.43x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-09-30) in USD | $1.10 |
ASX:MSB Share Price * | ASX (2019-02-19) in AUD | A$1.18 |
ASX:MSB Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $0.84 |
Australia Biotechs Industry PB Ratio | Median Figure of 47 Publicly-Listed Biotechs Companies | 3.14x |
Australia Market PB Ratio | Median Figure of 1,664 Publicly-Listed Companies | 1.64x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = ASX:MSB Share Price ÷ Book Value per Share (both in USD) = 0.84 ÷ 1.10 |
0.76x |
* Primary Listing of Mesoblast.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
How is Mesoblast expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
Data Point | Source | Value (per year) |
---|---|---|
ASX:MSB Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 67.5% |
ASX:MSB Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 59.9% |
Australia Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 10% |
Australia Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
Australia Market Earnings Growth Rate | Market Cap Weighted Average | 5.9% |
Australia Market Revenue Growth Rate | Market Cap Weighted Average | 2.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
---|---|---|---|---|
2023-06-30 | 804 | 363 | 2 | |
2022-06-30 | 419 | -6 | 3 | |
2021-06-30 | 326 | -77 | -70 | 3 |
2020-06-30 | 65 | -24 | -95 | 4 |
2019-06-30 | 20 | -66 | -90 | 6 |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-09-30 | 28 | -74 | -48 |
2018-06-30 | 17 | -75 | -35 |
2018-03-31 | 16 | -78 | -42 |
2017-12-31 | 16 | -84 | -30 |
2017-09-30 | 3 | -95 | -64 |
2017-06-30 | 2 | -95 | -77 |
2017-03-31 | 29 | -90 | -1 |
2016-12-31 | 32 | -86 | -8 |
2016-09-30 | 35 | -81 | -11 |
2016-06-30 | 43 | -88 | -4 |
2016-03-31 | 20 | -97 | -83 |
2015-12-31 | 20 | -98 | -88 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
---|---|---|---|---|
2023-06-30 | ||||
2022-06-30 | ||||
2021-06-30 | -0.16 | -0.16 | -0.16 | 1.00 |
2020-06-30 | -0.04 | 0.02 | -0.10 | 2.00 |
2019-06-30 | -0.18 | -0.18 | -0.18 | 2.00 |
Date (Data in USD Millions) | EPS * |
---|---|
2018-09-30 | -0.10 |
2018-06-30 | -0.08 |
2018-03-31 | -0.09 |
2017-12-31 | -0.07 |
2017-09-30 | -0.16 |
2017-06-30 | -0.19 |
2017-03-31 | -0.00 |
2016-12-31 | -0.02 |
2016-09-30 | -0.03 |
2016-06-30 | -0.01 |
2016-03-31 | -0.24 |
2015-12-31 | -0.26 |
*GAAP earnings excluding extraordinary items.
How has Mesoblast performed over the past 5 years?
All data from Mesoblast Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-09-30 | 27.80 | -47.77 | 22.51 | 69.05 |
2018-06-30 | 17.34 | -35.29 | 21.91 | 65.93 |
2018-03-31 | 16.21 | -41.64 | 23.84 | 64.33 |
2017-12-31 | 16.04 | -30.29 | 23.32 | 61.46 |
2017-09-30 | 3.19 | -64.04 | 22.56 | 60.28 |
2017-06-30 | 2.41 | -76.82 | 23.01 | 58.91 |
2017-03-31 | 28.73 | -1.34 | 21.69 | 57.37 |
2016-12-31 | 31.97 | -8.49 | 21.59 | 55.46 |
2016-09-30 | 35.43 | -10.77 | 22.42 | 52.93 |
2016-06-30 | 42.55 | -4.13 | 22.50 | 50.01 |
2016-03-31 | 19.85 | -83.00 | 24.99 | 54.09 |
2015-12-31 | 19.94 | -88.30 | 26.31 | 55.52 |
2015-09-30 | 20.31 | -93.86 | 28.13 | 60.85 |
2015-06-30 | 19.76 | -96.24 | 29.54 | 62.65 |
2015-03-31 | 21.25 | -84.77 | 26.05 | 55.61 |
2014-12-31 | 23.50 | -84.42 | 24.85 | 55.26 |
2014-09-30 | 26.12 | -75.37 | 24.15 | 50.82 |
2014-06-30 | 23.39 | -75.53 | 24.40 | 50.93 |
2014-03-31 | 30.10 | -67.78 | 23.32 | 49.38 |
2013-12-31 | 35.50 | -57.90 | 21.45 | 46.13 |
2013-09-30 | 37.41 | -56.40 | 21.38 | 45.80 |
2013-06-30 | 31.78 | -56.45 | 20.91 | 43.79 |
2013-03-31 | 35.78 | -60.61 | 25.47 | 47.58 |
2012-12-31 | 35.35 | -56.90 | 27.11 | 45.26 |
2012-09-30 | 37.52 | -65.34 | 28.10 | 41.78 |
2012-06-30 | 39.18 | -72.82 | 24.62 | 37.89 |
2012-03-31 | 38.45 | -61.06 | 24.55 | 31.21 |
*GAAP earnings excluding extraordinary items.
How is Mesoblast's financial health and their level of debt?
All data from Mesoblast Company Filings, last reported 4 months ago.
Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-09-30 | 527.60 | 61.16 | 55.14 |
2018-06-30 | 546.01 | 59.40 | 37.76 |
2018-03-31 | 556.14 | 31.42 | 59.54 |
2017-12-31 | 575.61 | 0.00 | 47.39 |
2017-09-30 | 559.59 | 0.00 | 62.94 |
2017-06-30 | 516.77 | 0.00 | 45.76 |
2017-03-31 | 540.40 | 0.00 | 69.12 |
2016-12-31 | 510.52 | 0.00 | 33.90 |
2016-09-30 | 509.87 | 0.00 | 60.36 |
2016-06-30 | 528.16 | 0.00 | 80.94 |
2016-03-31 | 478.94 | 0.00 | 99.93 |
2015-12-31 | 492.75 | 0.00 | 120.78 |
2015-09-30 | 452.83 | 0.00 | 77.76 |
2015-06-30 | 467.99 | 0.00 | 110.70 |
2015-03-31 | 478.60 | 0.00 | 122.09 |
2014-12-31 | 478.60 | 0.00 | 122.09 |
2014-09-30 | 512.53 | 0.00 | 149.14 |
2014-06-30 | 539.18 | 0.00 | 185.22 |
2014-03-31 | 530.08 | 0.00 | 182.09 |
2013-12-31 | 570.37 | 0.00 | 226.81 |
2013-09-30 | 589.12 | 0.00 | 297.98 |
2013-06-30 | 576.98 | 0.00 | 291.84 |
2013-03-31 | 656.01 | 0.00 | 331.82 |
2012-12-31 | 470.87 | 0.00 | 185.49 |
2012-09-30 | 470.58 | 0.00 | 185.37 |
2012-06-30 | 490.15 | 0.00 | 210.44 |
2012-03-31 | 496.50 | 0.00 | 213.17 |
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
What is Mesoblast's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 22 Stocks | 2.4% |
Australia Market Average Dividend Yield | Market Cap Weighted Average of 420 Stocks | 4.4% |
Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
Australia Bottom 25% Dividend Yield | 25th Percentile | 2.7% |
Australia Top 25% Dividend Yield | 75th Percentile | 6.1% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
---|---|---|
2023-06-30 | ||
2022-06-30 | ||
2021-06-30 | ||
2020-06-30 | ||
2019-06-30 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast, Inc. He serves as a Director of Transplantation Immunology at Columbia University's New York. Prof. Itescu founded Mesoblast Limited in 2004 and served as its Chief Scientific Advisor since June 2004. He serves as Professor of Medicine at the University of Melbourne and has an outstanding international reputation in research and development in biotechnology. Prof. Itescu is on the Medical Faculties of both Columbia University in NewYork and Melbourne University. He is a faculty member of Monash University. He has established an outstanding international reputation in the fields of Cell Biology, immunology, autoimmune diseases, organ transplantation and heart failure. In these areas of focus, Prof. Itescu has gained broad experience, from basic research in the laboratory through to new drug development and clinical evaluation. He serves as the Chairman and Member of Scientific Advisory Board at Mesoblast Limited. Prof. Itescu has been an Executive Director of Mesoblast Limited since 2007 and served as its director since June 2004 until 2007. He serves as an Executive Director of Mesoblast, Inc. Prof. Itescu is a member of numerous national and international scientific bodies and professional societies, has consulted globally for many international pharmaceutical companies and has been an advisor to biotechnology and health care investment groups. Prof. Itescu served as a Member of Executive Committee of Alliance for Regenerative Medicine. He served as a Director of Diversa Limited (formelry Ambri Ltd.) from September 18, 2003 to December 20, 2006 and Zenyth Therapeutics Ltd. (formerly Amrad Corp. Ltd.) from July 17, 2003 to November 2006. He has served on the board of directors of several publicly listed life sciences companies. Prof. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. In 2011, Prof. Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Prof. Itescu holds a Medical Degree from Monash University and received his Specialty Training in Internal Medicine and Immunology/Rheumatology from New York University.
Average tenure and age of the Mesoblast management team in years:
Average tenure and age of the Mesoblast board of directors in years:
Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
---|---|---|---|---|---|---|---|---|---|---|
10. Feb 19 | Sell | Capital Research and Management Company | Company | 08. Mar 18 | 07. Feb 19 | -2,721,380 | A$1.22 | A$-3,306,476 | ||
15. Oct 18 | Sell | M&G Investment Management Limited | Company | 14. Dec 17 | 11. Sep 18 | -2,932,191 | A$1.49 | A$-4,367,871 | ||
15. Oct 18 | Buy | M&G Investment Management Limited | Company | 21. May 18 | 19. Jul 18 | 1,796,507 | A$1.44 | A$2,578,058 | ||
09. Mar 18 | Buy | Capital Research and Management Company | Company | 24. Mar 15 | 07. Mar 18 | 14,838,893 | A$1.84 | A$27,288,723 |
In 2011 Silviu Itescu was appointed CEO of Mesoblast Limited (ASX:MSB). … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Silviu Itescu's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleA look at the shareholders of Mesoblast Limited (ASX:MSB) can tell us which group is most powerful. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'.
Simply Wall St - – Full articleToday, I will be analyzing Mesoblast Limited’s (ASX:MSB) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Simply Wall St - – Full articleBeta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.
Simply Wall St - – Full articleWith the latest financial year loss of -US$76.81m and a trailing-twelve month of -US$41.64m, the US$696.58m market-cap alleviates its loss by moving closer towards its target of breakeven? … The most pressing concern for investors is MSB’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for MSB’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleMany investors are wondering the rate at which MSB will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for MSB, its year of breakeven and its implied growth rate. … Next Steps: This article is not intended to be a comprehensive analysis on MSB, so if you are interested in understanding the company at a deeper level, take a look at MSB’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Simply Wall St - – Full articleIn this article, I will take a quick look at Mesoblast Limited’s (ASX:MSB) recent ownership structure – an unconventional investing subject, but an important one. … Private Company Ownership Potential investors in MSB should also look at another important group of investors: private companies, with a stake of 2.05%, who are primarily invested because of strategic and capital gain interests. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.
Simply Wall St - – Full articleA popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect MSB to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleInsiders' net buying activities seem to bolster the idea of growth moving forward. … An alternative reason for recent trades could be insiders taking advantage of the share price volatility. … Next Steps: Mesoblast’s net buying tells us the stock is in favour with some insiders, though negative growth in expected earnings contests this assumption, whereas a highly volatile share price could be the driver to buy.
Simply Wall St - – Full articleMany investors are wondering the rate at which MSB will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for MSB’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 64.30% year-on-year, on average, which is rather optimistic! … For a more comprehensive look at MSB, take a look at MSB’s company page on Simply Wall St.
Simply Wall St - – Full article
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Name: | Mesoblast Limited |
MSB | |
Exchange: | ASX |
Founded: | 2004 |
A$576,822,032 | |
495,126,208 | |
Website: | http://www.mesoblast.com |
Address: |
Mesoblast Limited 55 Collins Street, Level 38, Melbourne, Victoria, 3000, Australia |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
ASX | MSB | Ordinary Shares | Australian Securities Exchange | AU | AUD | 16. Dec 2004 | |
OTCPK | MEOB.F | Ordinary Shares | Pink Sheets LLC | US | USD | 16. Dec 2004 | |
DB | LWB | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 16. Dec 2004 | |
CHIA | MSB | Ordinary Shares | Chi-X Australia | AU | AUD | 16. Dec 2004 | |
NasdaqGS | MESO | SPON ADR EACH REP 5 SHS | Nasdaq Global Select | US | USD | 15. Dec 2005 | |
DB | LWBA | SPON ADR EACH REP 5 SHS | Deutsche Boerse AG | DE | EUR | 15. Dec 2005 |
Biotechnology | |
Pharmaceuticals & Biotech |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/19 10:31 |
End of day share price update: | 2019/02/19 00:00 |
Last estimates confirmation: | 2019/02/06 |
Last earnings filing: | 2018/11/16 |
Last earnings reported: | 2018/09/30 |
Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.